Every 10-Q that MoonLake Immunotherapeutics (MLTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MLTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MLTX filings page.
MoonLake Immunotherapeutics is a clinical-stage biotech focused on Sonelokimab (SLK) for inflammatory skin and joint diseases. It reported a net loss of $131.5 million for the six months ended June 30, 2026, compared with $96.6 million a year earlier, driven by higher research and development and general and administrative expenses.
The company had $537.0 million in cash, cash equivalents and short-term marketable debt securities and working capital of $524.6 million, and management believes this will fund operations and capital expenditures to mid‑2028. Long‑term debt principal outstanding under its Hercules credit facility was $100.0 million.
Clinically, MoonLake reported strong week‑52 Phase 3 VELA results for SLK in hidradenitis suppurativa, achieving high HiSCR75 and HiSCR100 response rates and improved quality‑of‑life scores, and positive week‑16 primary endpoint results in the Phase 3 IZAR‑1 trial in psoriatic arthritis. The company also raised $189.8 million net in a June 2026 equity offering and continues to expand share‑based incentive programs.
MoonLake Immunotherapeutics reported a larger net loss for the quarter ended March 31, 2026 as it continued to invest heavily in its Sonelokimab (SLK) pipeline. Net loss was $69.7 million, compared with $40.6 million a year earlier, driven mainly by higher research and development spending of $54.5 million.
The company ended the quarter with $298.5 million in cash and cash equivalents and $59.4 million in short-term marketable debt securities, and stated this, together with recent equity proceeds, should fund operations to the end of 2027. Long-term debt rose to $99.0 million after drawing a second tranche under its $500.0 million secured term loan facility.
Clinically, MoonLake highlighted continued positive Phase 3 data for SLK in hidradenitis suppurativa, supportive FDA feedback that its existing HS trials can establish substantial evidence of effectiveness, and progress across Phase 3 psoriatic arthritis and Phase 2 programs in palmoplantar pustulosis and axial spondyloarthritis, alongside preparation for a planned HS biologics license application submission in the third quarter of 2026.
MoonLake Immunotherapeutics reported third-quarter 2025 results showing higher R&D investment and a wider loss as it advances sonelokimab. R&D expenses were $60.6M and total operating expenses reached $71.4M, leading to a net loss of $70.7M for the quarter and $167.3M year-to-date. Interest expense was $3.2M, reflecting new debt.
Liquidity remains strong with cash and cash equivalents of $350.7M and short‑term marketable securities of $29.7M. Management states this resources base funds operations into the second half of 2027. Shareholders’ equity was $288.9M, and long‑term debt stood at $73.7M following a $75M initial draw under a $500M credit facility.
Clinical progress was mixed: the company announced that VELA‑1 met its primary endpoint in hidradenitis suppurativa, while a higher‑than‑expected placebo response prevented VELA‑2 from meeting its pre‑specified primary endpoint. As a result, the company did not achieve certain loan milestones tied to additional tranches under the facility.